Today: 9 April 2026
Lululemon stock slips today as founder Chip Wilson launches proxy fight over board shake-up
30 December 2025
2 mins read

Lululemon stock slips today as founder Chip Wilson launches proxy fight over board shake-up

NEW YORK, December 30, 2025, 14:50 ET — Regular session

  • lululemon shares fell about 0.6% as founder Chip Wilson pushed a proxy contest for board changes.
  • The company said its board will review Wilson’s nominees and outline a recommendation ahead of the 2026 annual meeting.
  • The challenge lands amid a CEO transition after Calvin McDonald said he will step down on Jan. 31. Reuters+2SEC+2

Shares of lululemon athletica inc. fell about 0.6% to $211.30 in afternoon trading on Tuesday after founder Chip Wilson launched a proxy fight — a campaign to win shareholder votes for board seats — seeking to reshape the board. The stock had gained about 2% on Monday, Reuters reported. Reuters

The board fight comes as the athletic apparel maker searches for a permanent chief executive after Calvin McDonald said he would step down on Jan. 31. Chief financial officer Meghan Frank and chief commercial officer André Maestrini are set to serve as interim co-CEOs, the company said. Lululemon

Why it matters now: lululemon shares have lost nearly half their value in 2025 as the company has struggled to regain momentum with younger, affluent shoppers and faced fast-growing rivals such as Alo Yoga and Vuori. Activist pressure has also risen after Elliott Management disclosed a stake earlier this month, Reuters reported. Reuters

Wilson said he has nominated former On Running co-CEO Marc Maurer, former ESPN chief marketing officer Laura Gentile and former Activision CEO Eric Hirshberg for election at the 2026 annual meeting. He also plans to press for the board to be “declassified” — meaning all directors would face annual elections rather than staggered terms — a filing showed. Reuters+1

lululemon said its board will evaluate the nominees under its governance process and urged shareholders not to take any action for now. The company said it had asked Wilson to share nominee names earlier in an effort to avoid a “costly and distracting” contest, but he declined until submitting his notice. SEC

“Adding three new board members seems like something that Lululemon would be willing to do,” Morningstar analyst David Swartz said, while noting only Maurer has direct experience in the category. Reuters

The move in lululemon contrasted with a largely steady broader market, with the SPDR S&P 500 ETF down slightly and the consumer discretionary sector off about 0.2%. Athletic-apparel peers were mixed, with Nike down marginally while Under Armour jumped more than 8%.

Wilson holds a 4.27% stake in lululemon as of December, according to LSEG data cited by Reuters. A person familiar with his thinking told Reuters he was not working with any other investor on the board challenge. Reuters

Elliott disclosed a roughly $1 billion stake earlier this month, and Reuters has reported the activist had been working with former Ralph Lauren executive Jane Nielsen as a possible CEO candidate. Wilson has spoken with Nielsen but would not support a CEO selected before board changes, the source said. Reuters

In its response, lululemon defended its board’s record and pointed to shareholder returns, saying cumulative share repurchases since fiscal 2015 exceed $5.5 billion. The company also said it expects fiscal 2025 revenue of about $11.0 billion based on its guidance. SEC

Investors are now watching for the next round of filings ahead of the 2026 annual meeting, including the company’s definitive proxy statement and any detailed platform from Wilson’s camp. The CEO search remains a near-term swing factor, with the board describing its aim to find a leader who can guide the company through “growth and transformation.” SEC+1

lululemon trades at about 11 times earnings, according to market data, keeping sentiment tightly tied to governance headlines and any clarity on leadership in the weeks ahead.

Stock Market Today

  • Primary Health Properties Shares Drop 11%, Yield Tops 8% Offering Attractive Income Play
    April 9, 2026, 2:59 AM EDT. Primary Health Properties (LSE:PHP) has seen its share price fall 11% in a month amid market turmoil, pushing its dividend yield to 8%. Investors can currently buy 5,411 shares with £5,000, potentially securing around £400 in annual dividends. The FTSE 250-listed REIT's dividends have grown about 8% annually since the mid-1990s, outpacing average FTSE 100 yields. Rising UK healthcare demand, especially from an aging population, supports long-term growth in medical facility investments. Recent Bank of England rate hike expectations have pressured REIT valuations and borrowing costs, challenging the firm after its acquisition of Assura. However, Primary Health Properties has navigated such headwinds before and appears positioned to maintain its dividend track record.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 3:06 AM EDT Primary Health Properties Shares Drop 11%, Yield Tops 8% Offering Attractive Income Play April 9, 2026, 2:59 AM EDT. Primary Health Properties (LSE:PHP) has seen its share price fall 11% in a month amid market turmoil, pushing its dividend yield to 8%. Investors can currently buy 5,411 shares with £5,000, potentially securing around £400 in annual dividends. The FTSE 250-listed REIT's dividends have grown about 8% annually since the mid-1990s, outpacing average FTSE 100 yields. Rising UK healthcare demand, especially from an aging population, supports
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib
Previous Story

Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

Why Caris Life Sciences (CAI) stock is down today as biotech slips
Next Story

Why Caris Life Sciences (CAI) stock is down today as biotech slips

Go toTop